Merck Sharp + Dohme Corp.

Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Carrie A Rutkowski

Phillip Dan Cook

Thazha P Prakash

Balkrishen Bhat

David Brian Olsen

Malcolm Maccoss

Haoyun An

Charles John Guinosso

Anne Bettina Eldrup

Robert L LaFemina

Joanne E Tomassini

Amy L Simcoe

Neelima Bhat

Dawn L Hall

Mario A Valenciano

Steven S Carroll

Robert L Lafemina

Marija Prhavc

Anne B Eldrup

Amy L Himmelberger

Lawrence C Kuo

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

Growing community of inventors

Lansdale, PA, United States of America

Carrie A Rutkowski